Clinical trials: Flu
Interpandemic Influenza
Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009
Trial for annual approval of interpandemic influenza vaccines
- Trial name
- NCT00734734
- Testing
- Seasonal Influenza Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza Vaccine, Healthcare Workers
Nudge and Motivational Interviewing Interventions to Improve Influenza Vaccine Uptake Among Healthcare Workers in China
The goal of this clinical trial is to learn if nudge-based interventions and motivational interviewing work to improve influenza vaccination uptake among healthcare workers in China.
- Trial name
- NCT07157163
- Testing
- Phase 1: standardized nudge messages, Phase 1: personalized nudge messages + chatbot, Phase 2: motivational Interviewing
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Influenza, Human
BPL-1357 Against H1N1 Influenza Virus Challenge
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it.
- Trial name
- NCT07215858
- Testing
- BPL-1357 IM, BPL-1357 IN
- Where
- 2 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Influenza
ACTIVATE in Public Housing
This multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention sets out to mitigate uptake barriers and non-adherence to vaccination schedules as recommended by the CDC and increase…
- Conditions
- Pneumonia, Influenza, Varicella Zoster, Meningitis
- Trial name
- NCT06075732
- Testing
- Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
Influenza Prophylaxis
Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/0.5mL of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01863849
- Testing
- Vaccination with Fluval AB suspension for injection
- Where
- 3 sites in Hungary
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults
- Trial name
- NCT00958126
- Testing
- CSL425
- Where
- 11 sites in United States
- Volunteers
- 1,313 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge
After prophylactic vaccination with CR8020, a monoclonal antibody, subjects will be challenged with the H3N2 virus. The protective efficacy, safety, tolerability, pharmacokinetics, and potential immunogenicity will be assessed.
- Trial name
- NCT01938352
- Testing
- CR8020
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia
- Trial name
- NCT05079152
- Testing
- COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Influenza
Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age
A multi-center, open-label, escalating dose-ranging study to assess the safety, reactogenicity, and immunogenicity of four different VAX125 vaccine doses; 0.5 µg, 1.0 µg, 2.0 µg, or 3.0 µg, delivered i.m.
- Trial name
- NCT00966238
- Testing
- VAX125
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
COVID-19
Max COVID19- Study
In view of the increasing cases of COVID-19 in India and the possibility of the exponential rise of the cases, this study has been designed to collect data of the healthcare workers of Max Hospital and the general population.
- Trial name
- NCT04339608
- Where
- India
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Max Healthcare Insititute Limited
Respiratory Infections
Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults.
The purpose of this study is to investigate whether fish oil containing free fatty acids affects people's susceptibility to viral infections such as colds, influenza, and COVID-19, as well as the course of these illnesses.
- Trial name
- OmegaCold FFA (NCT07314593)
- Testing
- Omega-3 oil with 2% Free Fatty Acids, Vegatable oil
- Where
- Iceland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Landspitali University Hospital
Influenza
Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers
This study seeks to determine the incidence and transmission of avian influenza viruses in humans exposed to poultry. Enrolled subjects will be selected from five different rural areas (villages) in the Nile delta region in Egypt…
- Trial name
- NCT02459171
- Testing
- Questionnaire, Blood sample, Nasal wash
- Where
- Egypt
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Influenza Caused by the 2009 H1N1 Influenza Virus
Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11
A cohort of 3000 adults is followed to evaluate the effectiveness of the monovalent 2009 H1N1 vaccines used 2009-2010 and seasonal influenza vaccines used 2010-2011 in preventing the first laboratory-confirmed 2009 H1N1 influenza…
- Trial name
- NCT01206114
- Testing
- Follow-up
- Where
- Finland
- Volunteers
- 2,351 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Influenza
A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults
This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe…
- Trial name
- CSL's IVV (NCT00562484)
- Testing
- CSL Limited Influenza Vaccine
- Where
- 24 sites in Australia, New Zealand
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults
The purpose of this study is to evaluate immunological efficacy and safety of GC3110B versus GCFLU Quadrivalent Inj. among healthy adults in 18 to 60 years of age.
- Trial name
- NCT02915809
- Testing
- GC3110B vaccine, GCFLU Quadrivalent Inj. vaccine
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Seasonal Influenza, Influenza
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a…
- Conditions
- Seasonal Influenza, Influenza, Influenza Due to Unspecified Influenza Virus, Human Influenza
- Trial name
- NCT01342796
- Testing
- MF59C.1-adjuvanted subunit influenza vaccine, Sub unit, Inactivated, Influenza vaccine
- Where
- 2 sites in Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children
This is a sequential phase I and II, controlled, double-blinded study to determine whether immune responses suggesting protection against influenza can safely be induced in young children by two reduced doses one month apart of…
- Trial name
- NCT00386542
- Testing
- Vaxigrip® trivalent inactivated influenza vaccine, Intradermal spacer on Biojector® 2000 jet injector
- Where
- Dominican Republic
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Pedro Moro
Seasonal Influenza
A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
A phase III clinical trial of the study of quadrivalent influenza vaccine developed by Sinovac Biotech will be conducted in Chinese children aged 6 to 35 months.
- Trial name
- NCT06049927
- Testing
- Quadrivalent influenza vaccine(0.25ml), Quadrivalent influenza vaccine(0.5ml), Trivalent influenza vaccine(BV)
- Where
- 5 sites in China
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.
- Trial name
- NCT01776541
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Avian Influenza, Influenza Immunisation
2017 A/H7N9 IIV Revaccination
This is a Phase II clinical trial in up to 420 males and non-pregnant females, 19 to 70 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03738241
- Testing
- A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
- Where
- 9 sites in United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.